Amazon, Berkshire Hathaway, JPMorgan health venture names a CTO

Serkan Kutan has been appointed chief technology officer to the healthcare joint venture between Amazon, Berkshire Hathaway and JPMorgan Chase & Co. The venture, still unnamed, was formed at the start of 2018.

Kutan called the role his “dream job” in a LinkedIn post. Prior to joining the venture, he was CTO of Zocdoc, a digital booking platform for the healthcare industry. He also previously served as principal engineer/architect of the eCommerce platform for Amazon and as vice president/architect for technology infrastructure at Goldman Sachs.

The hiring comes at a time when details about the venture have started to leak, though the scale of what the three companies hope to achieve is still mostly unknown. In recent court documents that became available over a lawsuit from UnitedHealthcare to block the hiring of a former employee, the venture noted it plans to tackle healthcare costs and needs for employees of the three companies only.

The healthcare entity has also ramped up hiring of executives and other positions over the last several months.

Beyond hiring the CTO, the venture is also hiring for other positions, Kutan noted.

“The challenging task will require the best technology team in health care,” he wrote, while directing readers to a link with open jobs.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.